Risk Assessment of Iron Overload in Repeated Transfusion

Abstract

Iron overload is a significant and potentially life-threatening complication in patients undergoing repeated blood transfusions, particularly those with chronic anemias such as thalassemia, sickle cell disease, and myelodysplastic syndromes. This review aims to provide a comprehensive evaluation of the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic approaches, management strategies, and emerging therapies for transfusional iron overload, with a focus on evidence-based recommendations for clinical practice. Early identification and targeted interventions are critical to mitigating morbidity and mortality associated with iron toxicity.

Introduction

Repeated transfusion therapy is essential in the management of various chronic hematological disorders. However, the cumulative iron received via transfused erythrocytes surpasses the body’s excretory capacity, thereby precipitating iron overload. This iatrogenic complication is associated with progressive organ dysfunction, particularly affecting the liver, heart, and endocrine glands. Accurate assessment and timely intervention are paramount to optimizing patient outcomes. This article synthesizes recent clinical evidence and guideline-based recommendations in the assessment and management of transfusional iron overload.

Epidemiology / Disease Burden

The prevalence of transfusional iron overload is highest among patients with transfusion-dependent thalassemia major, with over 90% developing iron overload without chelation therapy. Patients with sickle cell disease (SCD) also face substantial risk, particularly with chronic transfusion regimens for stroke prophylaxis or severe anemia. In myelodysplastic syndromes (MDS), transfusional iron overload is increasingly recognized as a contributor to morbidity and reduced survival. Recent registry data indicate that up to 70% of MDS patients receiving regular transfusions develop significant iron accumulation over time. The global burden is rising with improved survival rates in these populations, highlighting the need for vigilant risk assessment and management.

Pathophysiology

Each unit of packed red blood cells contains approximately 200-250 mg of elemental iron. The human body lacks a regulated pathway for iron excretion, resulting in progressive iron accumulation with every transfusion. Excess iron initially saturates transferrin, the main iron-transporting protein. Once transferrin saturation exceeds 60-70%, non-transferrin bound iron (NTBI) appears in the plasma, which is highly reactive and catalyzes the formation of free radicals via the Fenton reaction. This leads to oxidative tissue injury, particularly in the liver (causing fibrosis and cirrhosis), heart (resulting in cardiomyopathy and arrhythmias), and endocrine glands (causing diabetes, hypogonadism, and other dysfunctions).

Risk Factors

The risk of iron overload is influenced by the frequency and cumulative number of transfusions, underlying disease state, baseline iron stores, and genetic factors affecting iron metabolism. Patients with ineffective erythropoiesis, such as thalassemia major, have increased intestinal iron absorption in addition to transfusional loading. Comorbidities affecting liver function can exacerbate iron toxicity. Genetic polymorphisms in hemochromatosis genes (e.g., HFE mutations) may further predispose to more severe organ damage.

Clinical Features

Iron overload is often insidious in onset, with organ damage developing over years. Hepatic involvement manifests as hepatomegaly, elevated transaminases, fibrosis, and eventual cirrhosis. Cardiac iron deposition is the leading cause of mortality, presenting as restrictive or dilated cardiomyopathy, arrhythmias, and congestive heart failure. Endocrine complications include hypogonadotropic hypogonadism, diabetes mellitus, hypothyroidism, and growth failure, particularly in pediatric populations. Clinical suspicion should be heightened in patients with a history of frequent transfusions and compatible symptoms or laboratory abnormalities.

Diagnosis

Diagnosis relies on a combination of clinical assessment and laboratory evaluation. Serum ferritin is a widely used, albeit nonspecific, surrogate marker for body iron stores. Transferrin saturation provides additional information on iron loading, especially in the early stages. Advanced imaging, particularly T2*-weighted magnetic resonance imaging (MRI), allows quantification of hepatic and myocardial iron concentration and is now considered the gold standard for noninvasive assessment. Liver biopsy is reserved for select cases where other modalities are inconclusive.

Treatment & Management

The cornerstone of management is iron chelation therapy, initiated based on established ferritin or organ iron thresholds. Options include deferoxamine (parenteral), deferasirox (oral), and deferiprone (oral), each with distinct pharmacokinetic profiles and adverse effect considerations. Regular monitoring of iron indices and organ function guides therapy adjustments. Supportive care includes management of complications such as heart failure, diabetes, and endocrine insufficiency. Transfusion minimization strategies, when feasible, are also beneficial.

Recent Advances / Emerging Therapies

Recent years have witnessed the development of novel oral chelators with improved efficacy and tolerability profiles. Combination chelation regimens are being explored for patients with refractory iron overload. Advances in imaging, such as quantitative MRI mapping, enable earlier detection of organ-specific iron deposition and more precise monitoring of therapeutic response. Gene therapies targeting underlying hematological disorders may reduce transfusion requirements and, consequently, iron overload risk. Research into hepcidin modulators offers promise as future therapeutic options for iron homeostasis regulation.

Guideline Recommendations

International guidelines, including those from the Thalassemia International Federation and American Society of Hematology, recommend regular monitoring of serum ferritin, annual or biennial liver and cardiac MRI, and early initiation of chelation therapy in patients with ongoing transfusional iron loading. Individualized risk assessment and multidisciplinary care are emphasized to optimize outcomes and minimize complications. Lifelong surveillance is advised, given the chronic nature of iron toxicity and the evolving risk profile with age and comorbidity.

Conclusion

Iron overload remains a critical concern in transfusion-dependent patients, contributing to significant long-term morbidity and mortality. Advances in diagnostic modalities and chelation therapy have markedly improved prognosis, but timely risk assessment and personalized management remain essential. Ongoing research into novel therapeutics and disease-modifying interventions holds promise for further reducing the burden of transfusional iron overload. Clinicians must maintain a high index of suspicion and adhere to evidence-based protocols to optimize care for this vulnerable population.